BY JULIE STEENHUYSEN: Abbott Laboratories (ABT.N) plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.
Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. This next-generation device has been approved in Europe and is now under U.S. regulatory review.
Abbott’s plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday. (read more)
BY ADITI JAIN: Diabetes, an increase in blood glucose levels, is an emerging health problem especially in developing countries. According to the World Health Organisation, India had 69 million diabetic individuals in 2015 and the number is projected
to go up to 98 million by 2030. The problem is more serious for Asians as their genetic makeup puts them at a greater risk of diabetes at a younger age than their European counterparts.
If left untreated, diabetes can give rise to serious health conditions like blindness, kidney failure, and heart-related problems. Apart from genetic factors, the occurrence of diabetes is related to food preferences and lifestyles. Therefore, understanding the link between consumption of various foods and prevalence of diabetes in different states can help in devising effective strategies to address the problem. (read more)
BY DLIFE EDITORS: AstraZeneca announced yesterday that the U.S. Food and Drug Administration (FDA) did not approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with Type 1 diabetes.
The FDA issued the drugmaker a complete response letter regarding the supplemental New Drug Application (sNDA) for Farxiga.
Farxiga is already approved in the United States for use in Type 2 diabetes. The company plans to work with the FDA to discuss the next steps. (read more)
BY JACK WOODFIELD: A group of more than 50 doctors are calling for the US government to revise its view on low carb diets and include the approach in its new guidelines.
The US Department of Agriculture (USDA) updates its Dietary Guidelines every five years, and doctors are advocating for low carb eating to be included the 2020 edition.
The open letter, which was published on Friday 12 July by the New York Times and Washington Post newspapers, argues that previous guidelines have failed with 72% of adults in the US now classed as overweight or obese, while 52% either have type 2 diabetes or are high risk of the condition.
The letter states: “Since the US Dietary Guidelines were introduced in 1980, the obesity and diabetes rates in America have more than doubled. Clearly, the guidelines are not working and are in need of a dramatic overhaul.” (read more)
BY THE ECONOMIC TIMES: Researchers at the Karolinska Institute’s Aging Research Center in Stockholm revealed in a study that people who have prediabetes are less likely to develop diabetes, returning to normal blood sugar levels.
While this spells good news for people worried about their prediabetes diagnosis, experts state that lifestyle changes aid this phenomenon.
“A person with prediabetes has high blood sugar levels, so they should limit their sugar intake as much as possible in order to control ..
“When choosing foods, consider opting for ones with a lower glycemic index (GI) of 55 or less,” she added. (read more)